445PDDurability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
Abstract Background Genomic rearrangements involving NTRK1/2/3 result in constitutively active TRK fusion proteins that are oncogenic drivers in multiple pediatric and adult cancers. Larotrectinib is a selective TRK inhibitor approved by the FDA in 2018 for the treatment of any TRK fusion cancer bas...
Saved in:
Published in | Annals of oncology Vol. 30; no. Supplement_5 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford University Press
01.10.2019
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Genomic rearrangements involving NTRK1/2/3 result in constitutively active TRK fusion proteins that are oncogenic drivers in multiple pediatric and adult cancers. Larotrectinib is a selective TRK inhibitor approved by the FDA in 2018 for the treatment of any TRK fusion cancer based on a primary analysis in 55 patients from 3 clinical trials [Drilon et al. NEJM 2018]. For the first time, we now report median duration of response (DOR) data in this primary cohort, as well as updated data in an expanded cohort of 159 total TRK fusion patients treated with larotrectinib, with 153 (55 primary + 98 supplemental) evaluable for efficacy.
Methods
Patients with TRK fusion cancer detected by local molecular profiling were treated with larotrectinib across 3 studies (NCT02122913, NCT02637687, and NCT02576431). Disease status was assessed by investigators using RECIST 1.1. Data cut-off was 19 February 2019.
Results
In the primary cohort of 55 patients with a median follow-up of 26 months, the median DOR in 44 patients with complete or partial responses was 35.2 months (95% CI 21.2–NE), with 17 progression events and 27 responses ongoing (range 1.6–44 months). The median PFS in the primary cohort was 25.8 months (95% CI 9.9–NE), with 27 patients having progressed. In the expanded combined dataset, the most common tumor types included soft tissue sarcoma (n = 36), infantile fibrosarcoma (n = 29), thyroid carcinoma (n = 26), salivary gland carcinoma (n = 21), and lung cancer (n = 12). The median age was 43 years, ranging from <1 month to 84 years; 33% <18 yr. The overall ORR was 79% (95% CI 72–85), with complete responses in 16%. Adverse events were primarily grade 1-2, with 13% of patients having had a grade 3-4 event related to larotrectinib. Only one patient discontinued due to an AE related to larotrectinib.
Conclusions
These data confirm the marked tissue-agnostic efficacy and long durability of response in patients with TRK fusion cancer treated with larotrectinib. Larotrectinib continued to demonstrate a favorable long-term safety profile. Screening patients for NTRK gene fusions should be actively considered.
Clinical trial identification
NCT02122913, NCT02637687, NCT02576431.
Editorial acknowledgement
Editorial assistance was provided by Michael Sheldon, PhD, of Scion, London, UK, funded by Bayer.
Legal entity responsible for the study
Bayer.
Funding
Bayer.
Disclosure
D.M. Hyman: Advisory / Consultancy: Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer Pharmaceuticals, Genentech / F. Hoffmann-La Roche; Research grant / Funding (self): Loxo Oncology, Bayer Pharmaceuticals, PUMA Biotechnology, AstraZeneca. C.M. van Tilburg: Advisory / Consultancy: Novartis, Bayer. D.S.W. Tan: Advisory / Consultancy: Novartis, Merck Loxo AstraZeneca Roche Pfizer; Travel / Accommodation / Expenses: Pfizer Boehringer Ingelheim Roche; Honoraria (self): BMS, Takeda, Novartis, Roche, Pfizer; Research grant / Funding (self): Novartis, GSK, AstraZeneca. A.F. Farago: Research grant / Funding (self): Bayer, Loxo Oncology; Advisory / Consultancy: Bayer, Loxo Oncology. T.W. Laetsch: Advisory / Consultancy: Novartis, Bayer, Loxo, Lill; Research grant / Funding (self): Pfizer Novartis Bayer Loxo Abbvie Amgen Atara Biotherapeutics BMS Lilly Epizyme GSK Janssen Jubilant Pharmaceuticals Novella Clinical, Servier. S. Kummar: Honoraria (self): Bayer; Advisory / Consultancy: Bayer; Travel / Accommodation / Expenses: Bayer. F. Doz: Research grant / Funding (institution): BMS, Celgene; Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Bayer, BMS, Celgene, Loxo Oncology, Servier. U.N. Lassen: Advisory / Consultancy: Bayer; Advisory / Consultancy: Pfizer. S.G. DuBois: Advisory / Consultancy: Loxo; Travel / Accommodation / Expenses: Loxo, Roche; Honoraria (self): Loxo; Research grant / Funding (self): Millennium, Merck, Novartis Roche Lilly Lilly Loxo BMS. R. McDermott: Travel / Accommodation / Expenses: Janssen-Cilag, Pfizer; Honoraria (self): Bayer, Sanofi, Janssen, Astellas, BMS, MSD, Pfizer, Novartis, Clovis; Research grant / Funding (self): Sanofi, Janssen, Bayer, Astellas. L. Mascarenhas: Research grant / Funding (institution): AstraZeneca, Eli Lilly. J.D. Berlin: Research grant / Funding (institution): PsiOxus, Bayer, EMD Serono, Symphogen, Roche/Genentech, Immunomedics, Novartis, Taiho, AbbVie (pharamcyclics), Boston Biomedical, FivePrime, Loxo, Incyte, Macrogenics; Honoraria (self): Nestle; Advisory / Consultancy: Rafeal, Seattle Genetics, EMD Serono, Bayer, eisai, Taiho, Armo,Gritstone, AstraZeneca, Celgene, Erytech. E.R. Rudzinski: Advisory / Consultancy: Bayer. M.C. Cox: Full / Part-time employment: Loxo Oncology. S. Nanda: Full / Part-time employment: Loxo Oncology. B.H. Childs: Full / Part-time employment: Bayer. A. Drilon: Advisory / Consultancy: Loxo Oncology/Bayer, Ignyta, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche, Takeda/Ariad/Millenium, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Bayer, Tyra; Research grant / Funding (self): Foundation Medicine; Licensing / Royalties: Wolters Kluwer; Honoraria (institution): Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho; Travel / Accommodation / Expenses: Merck; Advisory / Consultancy: MORE Health. D.S. Hong: Research grant / Funding (self): AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, MiRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seatt; Travel / Accommodation / Expenses: Loxo, MiRNA, ASCO, AACR, SITC, Genmab; Advisory / Consultancy: Alpha Insights, Axiom, Adaptimmune, Baxter, Bayer, Genentech, GLG, Group H, Guidepoint Global, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Seattle Genetics, Takeda, Trieza Therapeutics; Shareholder / Stockholder / Stock options: Molecular Match, OncoResponse, Presagia Inc. All other authors have declared no conflicts of interest. |
---|---|
AbstractList | Abstract
Background
Genomic rearrangements involving NTRK1/2/3 result in constitutively active TRK fusion proteins that are oncogenic drivers in multiple pediatric and adult cancers. Larotrectinib is a selective TRK inhibitor approved by the FDA in 2018 for the treatment of any TRK fusion cancer based on a primary analysis in 55 patients from 3 clinical trials [Drilon et al. NEJM 2018]. For the first time, we now report median duration of response (DOR) data in this primary cohort, as well as updated data in an expanded cohort of 159 total TRK fusion patients treated with larotrectinib, with 153 (55 primary + 98 supplemental) evaluable for efficacy.
Methods
Patients with TRK fusion cancer detected by local molecular profiling were treated with larotrectinib across 3 studies (NCT02122913, NCT02637687, and NCT02576431). Disease status was assessed by investigators using RECIST 1.1. Data cut-off was 19 February 2019.
Results
In the primary cohort of 55 patients with a median follow-up of 26 months, the median DOR in 44 patients with complete or partial responses was 35.2 months (95% CI 21.2–NE), with 17 progression events and 27 responses ongoing (range 1.6–44 months). The median PFS in the primary cohort was 25.8 months (95% CI 9.9–NE), with 27 patients having progressed. In the expanded combined dataset, the most common tumor types included soft tissue sarcoma (n = 36), infantile fibrosarcoma (n = 29), thyroid carcinoma (n = 26), salivary gland carcinoma (n = 21), and lung cancer (n = 12). The median age was 43 years, ranging from <1 month to 84 years; 33% <18 yr. The overall ORR was 79% (95% CI 72–85), with complete responses in 16%. Adverse events were primarily grade 1-2, with 13% of patients having had a grade 3-4 event related to larotrectinib. Only one patient discontinued due to an AE related to larotrectinib.
Conclusions
These data confirm the marked tissue-agnostic efficacy and long durability of response in patients with TRK fusion cancer treated with larotrectinib. Larotrectinib continued to demonstrate a favorable long-term safety profile. Screening patients for NTRK gene fusions should be actively considered.
Clinical trial identification
NCT02122913, NCT02637687, NCT02576431.
Editorial acknowledgement
Editorial assistance was provided by Michael Sheldon, PhD, of Scion, London, UK, funded by Bayer.
Legal entity responsible for the study
Bayer.
Funding
Bayer.
Disclosure
D.M. Hyman: Advisory / Consultancy: Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer Pharmaceuticals, Genentech / F. Hoffmann-La Roche; Research grant / Funding (self): Loxo Oncology, Bayer Pharmaceuticals, PUMA Biotechnology, AstraZeneca. C.M. van Tilburg: Advisory / Consultancy: Novartis, Bayer. D.S.W. Tan: Advisory / Consultancy: Novartis, Merck Loxo AstraZeneca Roche Pfizer; Travel / Accommodation / Expenses: Pfizer Boehringer Ingelheim Roche; Honoraria (self): BMS, Takeda, Novartis, Roche, Pfizer; Research grant / Funding (self): Novartis, GSK, AstraZeneca. A.F. Farago: Research grant / Funding (self): Bayer, Loxo Oncology; Advisory / Consultancy: Bayer, Loxo Oncology. T.W. Laetsch: Advisory / Consultancy: Novartis, Bayer, Loxo, Lill; Research grant / Funding (self): Pfizer Novartis Bayer Loxo Abbvie Amgen Atara Biotherapeutics BMS Lilly Epizyme GSK Janssen Jubilant Pharmaceuticals Novella Clinical, Servier. S. Kummar: Honoraria (self): Bayer; Advisory / Consultancy: Bayer; Travel / Accommodation / Expenses: Bayer. F. Doz: Research grant / Funding (institution): BMS, Celgene; Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Bayer, BMS, Celgene, Loxo Oncology, Servier. U.N. Lassen: Advisory / Consultancy: Bayer; Advisory / Consultancy: Pfizer. S.G. DuBois: Advisory / Consultancy: Loxo; Travel / Accommodation / Expenses: Loxo, Roche; Honoraria (self): Loxo; Research grant / Funding (self): Millennium, Merck, Novartis Roche Lilly Lilly Loxo BMS. R. McDermott: Travel / Accommodation / Expenses: Janssen-Cilag, Pfizer; Honoraria (self): Bayer, Sanofi, Janssen, Astellas, BMS, MSD, Pfizer, Novartis, Clovis; Research grant / Funding (self): Sanofi, Janssen, Bayer, Astellas. L. Mascarenhas: Research grant / Funding (institution): AstraZeneca, Eli Lilly. J.D. Berlin: Research grant / Funding (institution): PsiOxus, Bayer, EMD Serono, Symphogen, Roche/Genentech, Immunomedics, Novartis, Taiho, AbbVie (pharamcyclics), Boston Biomedical, FivePrime, Loxo, Incyte, Macrogenics; Honoraria (self): Nestle; Advisory / Consultancy: Rafeal, Seattle Genetics, EMD Serono, Bayer, eisai, Taiho, Armo,Gritstone, AstraZeneca, Celgene, Erytech. E.R. Rudzinski: Advisory / Consultancy: Bayer. M.C. Cox: Full / Part-time employment: Loxo Oncology. S. Nanda: Full / Part-time employment: Loxo Oncology. B.H. Childs: Full / Part-time employment: Bayer. A. Drilon: Advisory / Consultancy: Loxo Oncology/Bayer, Ignyta, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche, Takeda/Ariad/Millenium, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Bayer, Tyra; Research grant / Funding (self): Foundation Medicine; Licensing / Royalties: Wolters Kluwer; Honoraria (institution): Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho; Travel / Accommodation / Expenses: Merck; Advisory / Consultancy: MORE Health. D.S. Hong: Research grant / Funding (self): AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, MiRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seatt; Travel / Accommodation / Expenses: Loxo, MiRNA, ASCO, AACR, SITC, Genmab; Advisory / Consultancy: Alpha Insights, Axiom, Adaptimmune, Baxter, Bayer, Genentech, GLG, Group H, Guidepoint Global, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Seattle Genetics, Takeda, Trieza Therapeutics; Shareholder / Stockholder / Stock options: Molecular Match, OncoResponse, Presagia Inc. All other authors have declared no conflicts of interest. |
Author | DuBois, S G Drilon, A Albert, C M Laetsch, T W Kummar, S Farago, A F Hong, D S Geoerger, B Rudzinski, E R McDermott, R Mascarenhas, L Cox, M C Lassen, U N Childs, B H Hyman, D M Tan, D S W van Tilburg, C M Nanda, S Doz, F Berlin, J D |
Author_xml | – sequence: 1 givenname: D M surname: Hyman fullname: Hyman, D M organization: Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA – sequence: 2 givenname: C M surname: van Tilburg fullname: van Tilburg, C M organization: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany – sequence: 3 givenname: C M surname: Albert fullname: Albert, C M organization: Seattle Children’s Hospital, University of Washington, Seattle, WA, USA – sequence: 4 givenname: D S W surname: Tan fullname: Tan, D S W organization: Department of Medical Oncology, National Cancer Center Singapore, Singapore – sequence: 5 givenname: B surname: Geoerger fullname: Geoerger, B organization: Gustave Roussy Cancer Center, Université Paris-Sud, Université Paris-Saclay, Villejuif, France – sequence: 6 givenname: A F surname: Farago fullname: Farago, A F organization: Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, USA – sequence: 7 givenname: T W surname: Laetsch fullname: Laetsch, T W organization: Southwestern Medical Center/Children’s Health, University of Texas, Dallas, TX, USA – sequence: 8 givenname: S surname: Kummar fullname: Kummar, S organization: Stanford Cancer Center, Stanford University, Stanford, CA, USA – sequence: 9 givenname: F surname: Doz fullname: Doz, F organization: Institut Curie, SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Paris, France – sequence: 10 givenname: U N surname: Lassen fullname: Lassen, U N organization: Deptartment of Oncology, Rigshospitalet, Copenhagen, Denmark – sequence: 11 givenname: S G surname: DuBois fullname: DuBois, S G organization: Pediatric Oncology, Dana-Farber and Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA – sequence: 12 givenname: R surname: McDermott fullname: McDermott, R organization: Medical Oncology, St. Vincent’s University Hospital and Cancer Trials Ireland, Tallaght, Ireland – sequence: 13 givenname: L surname: Mascarenhas fullname: Mascarenhas, L organization: Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA – sequence: 14 givenname: J D surname: Berlin fullname: Berlin, J D organization: Department of Oncology, Vanderbilt University, Nashville, TN, USA – sequence: 15 givenname: E R surname: Rudzinski fullname: Rudzinski, E R organization: Seattle Children’s Hospital, University of Washington, Seattle, WA, USA – sequence: 16 givenname: M C surname: Cox fullname: Cox, M C organization: Clinical Development, Loxo Oncology, Inc., South San Francisco, CA, USA – sequence: 17 givenname: S surname: Nanda fullname: Nanda, S organization: Biostatistics, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA – sequence: 18 givenname: B H surname: Childs fullname: Childs, B H organization: Oncology, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA – sequence: 19 givenname: A surname: Drilon fullname: Drilon, A organization: Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA – sequence: 20 givenname: D S surname: Hong fullname: Hong, D S organization: Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA |
BookMark | eNqVz8FKAzEUBdAgFZyqH-DufYDTvsxkWrO2iuBGpPuQZjL4ZPoSkgxSv97K-AOuLlzuXZylWHBgL8SdxJVE3a4tnwu3PvbfjVIrxO2FqGS30fUDKrkQFeqmrbddq67EMudPRNzoRlfCK9W97XZTsgcaqZwgDJB8joGzhy8qHzDaFEryrhDTAYjB9tNYwHIP0fdkSyIH0RbyXPJ82b-_wjBlCgzOsvPpRlwOdsz-9i-vxf3z0_7xpQ5TNDHR0aaTkWh-KWammJlizpT2n_Mf0l5Wnw |
ContentType | Journal Article |
Copyright | European Society for Medical Oncology 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019 |
Copyright_xml | – notice: European Society for Medical Oncology 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019 |
DOI | 10.1093/annonc/mdz244.007 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain |
EISSN | 1569-8041 |
ExternalDocumentID | 10.1093/annonc/mdz244.007 |
GroupedDBID | --- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 0SF 1TH 23M 2WC 4.4 482 48X 53G 5GY 5VS 5WA 6J9 70D AAEDW AAJKP AAKUH AALRI AAMVS AAOGV AAPNW AAXUO ABEUO ABIXL ABJNI ABKDP ABLJU ABNKS ABOCM ABQLI ABVKL ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTO ADBBV ADEYI ADHKW ADHZD ADJQC ADOCK ADRIX ADRTK ADVLN ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AEWNT AFETI AFIYH AFOFC AFXEN AGINJ AGKEF AGSYK AHMBA AHXPO AIAGR AIJHB AITUG ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN AXUDD BAWUL BAYMD BHONS BTRTY BVRKM CDBKE CKLRP COF CS3 CZ4 DAKXR DIK DILTD D~K E3Z EBS EE~ F9B FDB GJXCC GX1 H5~ HAR HW0 HZ~ I09 IH2 IOX J21 KAQDR KOM KOP KQ8 KSI KSN M-Z M41 M49 MHKGH N9A NGC NOYVH NU- O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RW1 RXO TCURE TEORI TJX TR2 W8F WOQ X7H YAYTL YFH YKOAZ ZKX ~91 |
ID | FETCH-oup_primary_10_1093_annonc_mdz244_0073 |
ISSN | 0923-7534 |
IngestDate | Wed Sep 11 04:51:47 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_5 |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
LinkModel | OpenURL |
MergedId | FETCHMERGED-oup_primary_10_1093_annonc_mdz244_0073 |
ParticipantIDs | oup_primary_10_1093_annonc_mdz244_007 |
PublicationCentury | 2000 |
PublicationDate | 20191001 |
PublicationDateYYYYMMDD | 2019-10-01 |
PublicationDate_xml | – month: 10 year: 2019 text: 20191001 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Annals of oncology |
PublicationYear | 2019 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
SSID | ssj0006929 |
Score | 4.689415 |
Snippet | Abstract
Background
Genomic rearrangements involving NTRK1/2/3 result in constitutively active TRK fusion proteins that are oncogenic drivers in multiple... |
SourceID | oup |
SourceType | Publisher |
Title | 445PDDurability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF5qBfEiPvHNHvSksTXZpO6xWqVYK6JRegvZdAMFTaUkB_sH_NvOZjaP1lKqlxC26ZBlvmx2vpn5QsiJI6wA4h5mCGlygwU2PHMslEZo-_3ADBlsolWDc_fRab-y-57dq1S-S1VLSSwugvHMvpL_eBXGwK-qS_YPns2NwgCcg3_hCB6G40I-Zsx-arWSEWptp7nyEda8SiRYIWwdxumaFg2EojZSuQ0UB8i-0ZFJq-o-N_e5cxYmikNTBWGBLt79Jbc8jIIJQr79panUVsGvqtYod_CuEjkpH1v80lTKWvHUoJsZeMGqv4yMuOR5WVs8r8mxzDqalgEREnIIUq-5DjeUDFJ5UdbJGgRf-oHTlC317JnLPkpi-VEEk4eTj_4Ydi1KFb14y-W1h3OvXyLLZoPbEMUvN6_fOg_5S93hJso26vvPEuTcqqGZWmEEeyVL2xR3nazp-II2ESwbpCKjTbLS1RUUW0ROYYYOQ5phhioA0AnM0EFEU8xQwAzNMUMzzOBfADMUMUMRM9vk_O7WvWkbcIfeJwqaeFiIYHk4Ew9n4qkk7g6pwpDcJbQuRR0e7CufC5uxhuObQobcUY3ZDSWwtEdOFzK5v-B1B2S1ANghqcajRB7B_i8Wx9o3P6OeYz4 |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=445PDDurability+of+response+with+larotrectinib+in+adult+and+pediatric+patients+with+TRK+fusion+cancer&rft.jtitle=Annals+of+oncology&rft.au=Hyman%2C+D+M&rft.au=van+Tilburg%2C+C+M&rft.au=Albert%2C+C+M&rft.au=Tan%2C+D+S+W&rft.date=2019-10-01&rft.pub=Oxford+University+Press&rft.issn=0923-7534&rft.eissn=1569-8041&rft.volume=30&rft.issue=Supplement_5&rft_id=info:doi/10.1093%2Fannonc%2Fmdz244.007&rft.externalDocID=10.1093%2Fannonc%2Fmdz244.007 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon |